Cellectis Reports First Quarter 2026 Financial Results

May 12, 2026 - 03:06

Cellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs.

The company is advancing its pivotal Phase 2 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, known as the BALLI-01 study. The first interim analysis from this trial is expected in the fourth quarter of 2026, with a Biologics License Application submission anticipated in 2028.

In non-Hodgkin lymphoma, Cellectis is running the Phase 1 NATHALI-01 trial with eti-cel. The company expects to report the full Phase 1 dataset in the fourth quarter of 2026.

On the innovation front, Cellectis will present preclinical data on TALE-based epigenetic editing at the upcoming ASGCT meeting. This approach does not involve cutting DNA, representing a potentially safer method for genetic modification.

through its partnership with Servier and Allogene, interim pivotal data from the ALPHA3 trial of cema-cel has been reported. Among 24 patients in the cema-cel treatment arm, 58.3% achieved a complete response.

These developments mark steady progress across Cellectis' pipeline as the company moves toward key regulatory milestones in the coming years.